Similar articles

• [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].

  Bramlage P, Schönrock E, Odoj P, Wolf WP, Funken C. Bramlage P, et al. MMW Fortschr Med. 2008 Feb 7;150(6):40. MMW Fortschr Med. 2008. PMID: 18323344 Review. German. No abstract available.
• [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].

  [No authors listed] [No authors listed] Praxis (Bern 1994). 2004 Oct 13;93(42):1748. Praxis (Bern 1994). 2004. PMID: 15529964 German. No abstract available.
• [Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].

  Hildemann SK, Fischer HM, Bohlscheid V, Pittrow D. Hildemann SK, et al. MMW Fortschr Med. 2003 Apr 3;145(14):42. MMW Fortschr Med. 2003. PMID: 15072279 German. No abstract available.
• Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.

  Breithaupt-Grögler K, Gerhardt G, Lehmann G, Notter T, Belz GG. Breithaupt-Grögler K, et al. Int J Clin Pharmacol Ther. 1998 Aug;36(8):425-31. Int J Clin Pharmacol Ther. 1998. PMID: 9726695 Clinical Trial.
• Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.

  Kjeldsen SE, Os I, Høieggen A, Beckey K, Gleim GW, Oparil S. Kjeldsen SE, et al. Am J Cardiovasc Drugs. 2005;5(1):17-22. doi: 10.2165/00129784-200505010-00003. Am J Cardiovasc Drugs. 2005. PMID: 15631534 Review.